GAMMA Investing LLC Boosts Holdings in Qiagen (NYSE:QGEN)

GAMMA Investing LLC increased its holdings in shares of Qiagen (NYSE:QGEN) by 806.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 562 shares of the company’s stock after buying an additional 500 shares during the period. GAMMA Investing LLC’s holdings in Qiagen were worth $26,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. Toronto Dominion Bank acquired a new stake in shares of Qiagen in the second quarter valued at $27,000. Riverview Trust Co purchased a new stake in shares of Qiagen during the first quarter worth approximately $28,000. Park Place Capital Corp acquired a new position in Qiagen during the 1st quarter worth approximately $36,000. Massmutual Trust Co. FSB ADV increased its position in shares of Qiagen by 39.8% in the 3rd quarter. Massmutual Trust Co. FSB ADV now owns 853 shares of the company’s stock valued at $39,000 after purchasing an additional 243 shares during the last quarter. Finally, CWM LLC raised its holdings in shares of Qiagen by 19.1% in the 1st quarter. CWM LLC now owns 2,236 shares of the company’s stock valued at $96,000 after purchasing an additional 358 shares in the last quarter. 70.00% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

QGEN has been the topic of a number of recent analyst reports. HSBC downgraded Qiagen from a “buy” rating to a “hold” rating and set a $49.00 price objective on the stock. in a report on Thursday. Wolfe Research raised shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 target price on the stock in a research report on Thursday, June 27th. Robert W. Baird boosted their price target on shares of Qiagen from $49.00 to $52.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, Hsbc Global Res raised shares of Qiagen to a “hold” rating in a report on Thursday. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. Based on data from MarketBeat, Qiagen currently has an average rating of “Moderate Buy” and an average price target of $50.12.

Qiagen Price Performance

Shares of NYSE:QGEN opened at $43.00 on Friday. The stock’s 50 day moving average price is $45.10 and its 200 day moving average price is $43.53. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.77 and a quick ratio of 1.46. The stock has a market cap of $9.81 billion, a price-to-earnings ratio of 143.09, a PEG ratio of 3.36 and a beta of 0.39. Qiagen has a 12 month low of $34.74 and a 12 month high of $47.44.

Qiagen (NYSE:QGEN) last announced its earnings results on Wednesday, July 31st. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.52 by $0.03. The business had revenue of $496.00 million during the quarter, compared to the consensus estimate of $495.45 million. Qiagen had a return on equity of 12.92% and a net margin of 3.75%. Qiagen’s revenue was down .2% compared to the same quarter last year. During the same period in the prior year, the business posted $0.53 earnings per share. Equities research analysts anticipate that Qiagen will post 2.15 earnings per share for the current fiscal year.

Qiagen Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.